Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye Disease (NCT07471997) | Clinical Trial Compass
CompletedNot Applicable
Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye Disease
Mexico15 participantsStarted 2024-06-20
Plain-language summary
Thyroid eye disease frequently causes upper eyelid retraction, which can lead to ocular surface complications and cosmetic concerns. Several medical and surgical treatments have been proposed; however, minimally invasive therapies remain of interest.
This study evaluates the efficacy of local triamcinolone acetonide injection administered through transconjunctival and transseptal routes for the treatment of upper eyelid retraction in patients with inactive thyroid eye disease.
Patients with thyroid eye disease and upper eyelid retraction were treated with a combined subconjunctival and transcutaneous injection of triamcinolone acetonide. Clinical measurements including margin reflex distance 1 (MRD1), palpebral fissure height, visual acuity, intraocular pressure, and Clinical Activity Score (CAS) were evaluated before treatment and one month after intervention.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female participants aged 18 years or older.
* Diagnosis of thyroid eye disease.
* Presence of upper eyelid retraction defined as margin reflex distance 1 (MRD1) ≥ 4.5 mm.
* Clinical Activity Score (CAS) lower than 3 points.
* Ability and willingness to provide written informed consent.
Exclusion Criteria:
* Previous or current systemic corticosteroid treatment during the study period.
* Active thyroid eye disease with Clinical Activity Score (CAS) ≥ 3.
* Other causes of eyelid retraction.
* Need for urgent surgical management.
* Known allergy to triamcinolone acetonide.
* Known steroid responders.
* Diagnosis of advanced primary or secondary glaucoma according to Hodapp-Parrish-Anderson criteria.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Margin Reflex Distance 1 (MRD1)
Timeframe: Baseline and 1 Month After Treatment
Trial details
NCT IDNCT07471997
SponsorInstituto de Oftalmología Fundación Conde de Valenciana